title: Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.
abstract: The introduction of trastuzumab into clinical practice changed the natural course of HER2-positive breast cancer. Currently, treatment with trastuzumab represents the standard of care for HER2-positive breast cancer and this treatment has been approved in the adjuvant, neoadjuvant, and metastatic settings. Besides trastuzumab, two other anti-HER2 agents-lapatinib and pertuzumab-have been approved for the treatment of HER2-positive advanced breast cancer. Strong biologic data support the concept of dual HER2 blockade, with different anti-HER2 agents demonstrating complementary mechanisms of action. Several neoadjuvant and metastatic studies performed in HER2-positive breast cancer using dual HER2 blockade have been proven to outperform anti-HER2 monotherapies. These dual combinations of agents represent a promising therapeutic strategy that is now reaching clinical practice. In this review we describe the results of studies utilizing dual blockade in patients with HER2-positive breast cancer.
authors: Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1155 Herman P Pressler CPB5.3450, Houston, TX 77030, USA. ralvarez@mdanderson.org
authors: Ricardo H
authors: RH
authors: Alvarez
authors: Gabriel N
authors: GN
authors: Hortobagyi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
references: Lancet. 2010 Aug 28;376(9742):687-97
references: 20728210
references: J Clin Oncol. 2010 Mar 1;28(7):1124-30
references: 20124187
references: J Clin Oncol. 2006 Mar 1;24(7):1037-44
references: 16505422
references: Clin Cancer Res. 2009 Dec 15;15(24):7479-7491
references: 20008848
references: Sci Transl Med. 2012 Mar 28;4(127):127rv2
references: 22461643
references: Nat Rev Cancer. 2009 Jul;9(7):463-75
references: 19536107
references: J Clin Oncol. 2011 Aug 10;29(23):3126-32
references: 21730275
references: Cancer Res. 2009 Dec 15;69(24):9330-6
references: 19934333
references: N Engl J Med. 2012 Jan 12;366(2):109-19
references: 22149875
references: Cancer Cell. 2004 Aug;6(2):117-27
references: 15324695
references: J Clin Oncol. 2009 Dec 1;27(34):5838-47
references: 19884552
references: J Clin Oncol. 2010 Mar 1;28(7):1138-44
references: 20124182
references: EMBO J. 2000 Jul 3;19(13):3159-67
references: 10880430
references: Clin Cancer Res. 2007 Oct 1;13(19):5883-8
references: 17908983
references: Cancer. 1980 Dec 15;46(12 Suppl):2884-8
references: 7448733
references: Cancer Res. 2006 Feb 1;66(3):1630-9
references: 16452222
references: Lancet Oncol. 2012 Feb;13(2):135-44
references: 22257523
references: Science. 1987 Jan 9;235(4785):177-82
references: 3798106
references: Cancer Cell. 2007 Oct;12(4):395-402
references: 17936563
references: J Clin Oncol. 2013 May 10;31(14):1726-31
references: 23569315
references: Lancet Oncol. 2013 Nov;14(12):1183-92
references: 24095300
references: Cancer Cell. 2004 Apr;5(4):317-28
references: 15093539
references: Stem Cells. 1998;16(6):413-28
references: 9831867
references: J Clin Oncol. 2011 Sep 1;29(25):3351-7
references: 21788566
references: Cancer Cell. 2002 Aug;2(2):127-37
references: 12204533
references: J Clin Oncol. 2012 Jun 1;30(16):1989-95
references: 22493419
references: Ther Drug Monit. 2002 Feb;24(1):53-8
references: 11805723
references: Lancet Oncol. 2012 Jan;13(1):25-32
references: 22153890
references: N Engl J Med. 2007 Jul 5;357(1):39-51
references: 17611206
references: Breast Cancer Res Treat. 2008 Dec;112(3):533-43
references: 18188694
references: Cancer Res. 2004 Apr 1;64(7):2343-6
references: 15059883
references: N Engl J Med. 2006 Dec 28;355(26):2733-43
references: 17192538
references: Lancet. 2010 Jan 30;375(9712):377-84
references: 20113825
references: Lancet. 2012 Feb 18;379(9816):633-40
references: 22257673
references: Microvasc Res. 2008 May;76(1):15-22
references: 18440031
references: N Engl J Med. 2005 Oct 20;353(16):1659-72
references: 16236737
references: N Engl J Med. 2001 Mar 15;344(11):783-92
references: 11248153
references: N Engl J Med. 2005 Oct 20;353(16):1673-84
references: 16236738
references: N Engl J Med. 2011 Oct 6;365(14):1273-83
references: 21991949
references: J Clin Oncol. 2012 May 10;30(14):1594-600
references: 22393084